Literature DB >> 25907600

Deep molecular response in chronic myelogenous leukemia: ensuring accuracy and consistency.

H-W Ip1, C-C So2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25907600     DOI： 10.1038/leu.2015.93

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

Review 1.  How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.

Authors:  David M Ross; Timothy P Hughes
Journal:  Br J Haematol       Date:  2014-04-23       Impact factor: 6.998

Review 2.  Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.

Authors:  S Branford; N C P Cross; A Hochhaus; J Radich; G Saglio; J Kaeda; J Goldman; T Hughes
Journal:  Leukemia       Date:  2006-09-14       Impact factor: 11.528

3.  Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.

Authors:  Gabriel Etienne; Stéphanie Dulucq; Franck-Emmanuel Nicolini; Stéphane Morisset; Marie-Pierre Fort; Anna Schmitt; Madeleine Etienne; Sandrine Hayette; Eric Lippert; Caroline Bureau; Isabelle Tigaud; Didier Adiko; Gérald Marit; Josy Reiffers; François-Xavier Mahon
Journal:  Haematologica       Date:  2013-12-20       Impact factor: 9.941

Review 4.  Deep molecular response in chronic myeloid leukemia: the new goal of therapy?

Authors:  François-Xavier Mahon; Gabriel Etienne
Journal:  Clin Cancer Res       Date:  2013-10-28       Impact factor: 12.531

Review 5.  Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Authors:  N C P Cross; H E White; D Colomer; H Ehrencrona; L Foroni; E Gottardi; T Lange; T Lion; K Machova Polakova; S Dulucq; G Martinelli; E Oppliger Leibundgut; N Pallisgaard; G Barbany; T Sacha; R Talmaci; B Izzo; G Saglio; F Pane; M C Müller; A Hochhaus
Journal:  Leukemia       Date:  2015-02-05       Impact factor: 11.528

Review 6.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

7.  Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.

Authors:  Timothy P Hughes; Jeffrey H Lipton; Nelson Spector; Francisco Cervantes; Ricardo Pasquini; Nelma Cristina D Clementino; Pedro Enrique Dorlhiac Llacer; Anthony P Schwarer; Francois-Xavier Mahon; Delphine Rea; Susan Branford; Das Purkayastha; LaTonya Collins; Tomasz Szczudlo; Brian Leber
Journal:  Blood       Date:  2014-06-19       Impact factor: 22.113
  7 in total
  3 in total

1.  Response to Ho-Wan Ip and Chi-Chiu.

Authors:  N C P Cross; M C Müller; A Hochhaus
Journal:  Leukemia       Date:  2015-05-22       Impact factor: 11.528

2.  Reporting results for deep molecular responses in chronic myeloid leukemia.

Authors:  A A Morley
Journal:  Leukemia       Date:  2016-05-17       Impact factor: 11.528

3.  Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response.

Authors:  Aliza Mohd Yacob; Nor Asiah Muhamad; Kian Meng Chang; Hamidah Akmal Hisham; Yuslina Mat Yusoff; Latifah Ibrahim
Journal:  BMC Cancer       Date:  2022-03-26       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.